Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 975-981

  Thigpen, Anice E ^a   Cala, Kristine M ^a   Guileyardo, Joseph M ^a   Molberg, Kyle H ^a   McConnell, John D ^a   Russell, David W ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

neoplasm metastasis; prostatic neoplasms; transcription factors

Indexed keywords

COMPLEMENTARY DNA; EARLY GROWTH RESPONSE 1; MESSENGER RNA; NUCLEAR FACTOR; TESTOSTERONE PROPIONATE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CASTRATION; CELL DIVISION; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE VENTRAL LOBE; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030062287     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66361-4     Document Type: Article

References (20)

1. Boring, C. C., Squires, T. S. and Tong, T.: Cancer statistics, 1993. CA, 43: 7, 1993.
2. Stamey, T. A. and McNeal, J. E.: Adenocarcinoma of the prostate. In Campbell's Urology, 6th ed. Edited by P. C. Walsh, A. B. Retik, T. A., Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., vol. 2, chapt. 29, pp. 1159-1263, 1992.
3. Gleason, D. F.: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, chapt. 9, pp. 171-198, 1977.
4. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F., Schaafsma, H. E., Debruyne, F. M. and Isaacs, W. B.: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res., 52: 5104, 1992.
5. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
6. Sadasivan, R., Morgan, R., Jennings, S., Austenfeld, M., Van Veldhuizen, P., Stephens, R. and Noble, M.: Overexpression of her-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol., 150: 126, 1993.
7. Liang, P. and Pardee, A. B.: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science, 257: 967, 1992.
8. Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E. and Sager, R.: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263: 526, 1994.
9. Sambrook, J., Fritsch, E. F. and Maniatis, T.: Molecular Cloning, A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, 1989.
10. Lehrman, M. A., Russell, D. W., Goldstein, J. L. and Brown, M. S.: Alu-Alu recombination deletes splice acceptor sites and produces secreted low density lipoprotein receptor in a subject with familial hypercholesterolemia. J. Biol. Chem., 262: 3354, 1987.
11. Anderson, S., Bishop, R. W. and Russell, D. W.: Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. J. Biol. Chem., 264: 16249, 1989.
12. Berman, D. M. and Russell, D. W.: Cell-type-specific expression of rat steroid 5α-reductase isozymes. Proc. Natl. Acad. Sci., 90: 9359, 1993.
13. Herschman, H. R.: Primary response genes induced by growth factors and tumor promoters. Ann. Rev. Biochem., 60: 281, 1991.
14. Sukhatme, V. P.: The Egr transcription factor family: from signal transduction to kidney differentiation. Kidney Int., 41: 550, 1992.
15. Madden, S. L., Cook, D. M., Morris, J. F., Gashler, A., Sukhatme, V. P. and Rauscher, F. J., III: Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science, 253: 1550, 1991.
16. DeKlerk, D. P. and Coffey, D. S.: Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique. Biomorphometrics. Invest. Urol., 16: 240, 1978.
17. Dey, B. R., Sukhatme, V. P., Roberts, A. B., Sporn, M. B., Rauscher, F. J., III and Kim, S. J.: Repression of the transforming growth factor-β1 gene by the Wilms' tumor suppressor WT1 gene product. Molec. Endocr., 8: 595, 1994.
18. Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T. and Thompson, T. C.: Association of transforming growth factor-β1 with prostate cancer: an immunohistochemical study. Hum. Path., 24: 4, 1993.
19. Ohba, M., Shibanuma, M., Kuroki, T. and Nose, K.: Production of hydrogen peroxide by transforming growth factor-β1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J. Cell. Biol., 126: 1079, 1994.
20. Guileyardo, J. M., Johnson, W. D., Welsh, R. A., Akazaki, K. and Correa, P.: Prevalence of latent prostate carcinoma in two U.S. populations. J. Natl. Cancer Inst, 65: 311, 1980.